Floatz logo

Therapeutic Asset Ratings

395 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Dst-2970
Prostate Cancer
University of British ColumbiaP2CCC (48)
EXEMESTANE
Prostate Cancer
OHSU Knight Cancer InstituteP2CCC (48)
Memantine Hydrochloride
Prostate Cancer
Bin XuP2CCC (48)
OTL-38
Prostate Cancer
Indiana UniversityP2CCC (48)
PROPRANOLOL
Prostate Cancer
Zhongda HospitalP2CCC (48)
Radium Dichloride
Prostate Cancer
Memorial Sloan Kettering Cancer CenterP2CCC (48)
TESTOSTERONE ENANTATE
Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupP2CCC (48)
Tivozanib
Prostate Cancer
University of FloridaP2CCC (48)
[18f]f-resca-rt4
Prostate Cancer
RenJi HospitalP2/3CCC (48)
[18F]F-RESCA-T4
Prostate Cancer
RenJi HospitalP2/3CCC (48)
[68ga]ga-nota-t4
Prostate Cancer
RenJi HospitalP2/3CCC (48)
[68ga]p16-093
Prostate Cancer
Five Eleven Pharma, Inc.P1/2CCC (48)
Calcium folinate pentahydrate
Prostate Cancer
Parabilis Medicines, Inc.P1/2CCC (48)
Cryopreserved Umbilical Cord Allograft
Prostate Cancer
Hackensack Meridian HealthP2/3CCC (48)
Fampridine
Prostate Cancer
John ElfarP2/3CCC (48)
F-Dcfpyl
Prostate Cancer
H. Lee Moffitt Cancer Center and Research InstituteP2/3CCC (48)
Firmagon®
Prostate Cancer
Cancer Research AntwerpP2/3CCC (48)
Triptoreline
Prostate Cancer
Universitaire Ziekenhuizen KU LeuvenP2/3CCC (48)
Avelumab
Prostate Cancer
National Cancer Institute (NCI)P2CC (47)
177lu-p17-088
Prostate Cancer
First Affiliated Hospital of Fujian Medical UniversityP2CC (46)
177Lu-PSMA-I&T
Prostate Cancer
Medical University of ViennaP2CC (46)
2141-v11 antibody
Prostate Cancer
Memorial Sloan Kettering Cancer CenterP2CC (46)
68ga-hbed-ipsma
Prostate Cancer
Memorial Sloan Kettering Cancer CenterP2CC (46)
ac0010ma
Prostate Cancer
Sorrento Therapeutics, Inc.P2CC (46)
aciclovir
Prostate Cancer
Candel Therapeutics, Inc.P2CC (46)
Showing 151 to 175 of 395 assets
PreviousPage 7 of 16Next